Analysts predict that Kura Oncology Inc (NASDAQ:KURA) will report ($0.42) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Kura Oncology’s earnings, with estimates ranging from ($0.46) to ($0.40). Kura Oncology posted earnings of ($0.37) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 13.5%. The business is scheduled to issue its next quarterly earnings results on Monday, March 11th.
According to Zacks, analysts expect that Kura Oncology will report full year earnings of ($1.72) per share for the current year, with EPS estimates ranging from ($1.76) to ($1.70). For the next financial year, analysts expect that the firm will post earnings of ($2.01) per share, with EPS estimates ranging from ($2.73) to ($1.80). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Kura Oncology.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Monday, November 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.01.
Shares of Kura Oncology stock opened at $14.05 on Friday. Kura Oncology has a 12 month low of $10.20 and a 12 month high of $24.02. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.76 and a quick ratio of 14.76.
Institutional investors have recently made changes to their positions in the stock. Point72 Asset Management L.P. purchased a new position in shares of Kura Oncology in the 2nd quarter valued at about $2,412,000. Swiss National Bank purchased a new position in shares of Kura Oncology in the 2nd quarter valued at about $768,000. Prosight Management LP purchased a new position in shares of Kura Oncology in the 2nd quarter valued at about $5,240,000. BlackRock Inc. boosted its stake in shares of Kura Oncology by 25.5% in the 2nd quarter. BlackRock Inc. now owns 2,002,265 shares of the company’s stock valued at $36,440,000 after buying an additional 406,963 shares during the period. Finally, Sio Capital Management LLC boosted its stake in shares of Kura Oncology by 27.4% in the 2nd quarter. Sio Capital Management LLC now owns 837,604 shares of the company’s stock valued at $15,244,000 after buying an additional 180,193 shares during the period. Institutional investors own 79.28% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Further Reading: How to Invest in the Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.